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1. Introduction 
Previous chapters have widely discussed why patent valuation is important. The 
growing value of patents is also associated with a relevant need for information for 
different corporate stakeholders. Since financial reporting represents the foremost 
channel of information between the firm and its stakeholders, the issue of accounting 
valuation of patents is far from being trivial.  
The main objective of this chapter is to analyze accounting standards of different 
countries, such as the U.S. and Europe, and their implications for the accounting 
valuation of patents.  
The chapter deals with two interrelated aspects. First, it presents the general problems of 
evaluating patents for accounting purposes, discussing the problems of recognition, 
measurement and disclosure. Second, it focuses on the main divergences in the 
accounting valuation of patents between European (International Financial Reporting 
Standards) and U.S. accounting standards (U.S. General Accepted Accounting 
Principles). This comparison between accounting valuation criteria is also compelling in 
the light of ongoing international harmonization of accounting standards.i In 2005 all 
European companies traded in stock markets have compulsory adopted the International 
Financial Reporting Standards (hereby IFRS). Recently, the U.S. SEC issued proposals 
that could allow U.S. companies to use IFRS for fiscal years ending on or after 15 
December 2009 and could lead to mandatory transition to IFRS for domestic issuers 
starting for fiscal years ending on or after 15 December 2014.  
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The chapter is organized as follows. The next section will deal with the general 
problems of evaluating patents for accounting purposes. Sections 3 and 4 will examine, 
respectively, initial recognition and measurement of patents highlighting the main 
divergences between U.S. GAAP and IFRS. Section 5 will analyze the measurement of 
patents after initial recognition. The last section will draw some conclusions from the 
evidence presented in the chapter.  
 
2. The general problems of evaluating patents for accounting purposes 
Accounting standard setters establish the accounting rules under which firms report 
financial results to external parties. Consequently, accounting standards aim to reduce 
processing costs for financial statement users by providing a commonly accepted 
language that managers can use to communicate with investors (Healy and Palepu, 
2001).  
However, in spite of the growing relevance of patents, accounting values do not 
thoroughly reveal the economic values created by patents. There are three main 
problems related to the accounting valuation of patents: initial recognition, 
measurement and disclosure.  
The first one stems from the initial recognition that is the process of incorporating a 
patent in the balance sheet. It involves the accounting choice between capitalizing a 
patent in the balance sheet or expensing it in the income statement. Initial recognition 
criteria are different for purchased and internally generated patents. Thus, as discussed 
in the following sections, accounting standards generally allow capitalizing patents 
externally acquired, while those internally generated are mostly expensed. Even if from 
an economic perspective all patents could generate future benefits, however accounting 
standards requiring to expense those created internally are excluding a priori that they 
 3 
will generate future benefits. This asymmetric recognition substantially skews 
information provided by financial reports and significantly reduces the asset and equity 
values, above all for those small firms whose main assets are patents. This, in turn, 
might limit the comparability of the financial statements of companies that develop 
patents internally or buy them externally.  
A second problem is related to the measurement of patents. Measurement refers to the 
process of determining the monetary value at which a patent is recognised in the 
balance sheet. This involves the selection of the particular basis of measurement that, in 
the case of patents, mostly coincides with the historical cost. The measurement of 
capitalized patents at historical cost provides backward-looking information. Thus, 
financial reports supply no indication of efficiency of use and future exploitation 
potential of patents. The measurement at fair value could provide forward-looking 
information on patents since fair value is the amount for which a patent could be 
exchanged between knowledgeable, willing parties in an arm’s length transaction. 
However, the absence of public market prices of patents and the scarcity of comparable 
transactions make the evaluation of patents at fair value often unfeasible. 
The third problem is related to the disclosure on patents and to the deficiencies in patent 
recognition and measurement. Actually, financial statements include notes and 
supplementary information that is relevant to the needs of users about patents 
capitalized in the balance sheet or expensed in the income statement. However, the 
disclosure of information on patents is particularly scarce and the details provided 
substantially rely on firm’s willingness to disclose what is considered in most high-tech 
industries proprietary information. This created a high variation in the accuracy of 
information between and even within industries. In particular, for patents capitalized in 
the balance sheet, the notes to financial statement provide no indication of efficiency of 
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use and future exploitation potential of patents and disclose little systematic information 
about the capacity of the company to generate future revenues from them. As well, for 
those patents to be expensed in the income statement accounting standards do not 
mandate the disclosure of supplemental information. The financial statement of Agilent 
Technologies provides an example of shortcoming in accounting disclosure (see Box 1).  
 
Box 1 - Agilent Technologies Inc.: Disclosure on IPRs capitalized. 
 
Agilent Technologies is one of the most innovative companies among US semiconductor 
industry holding a patents portfolio of more than 3200 U.S. patents. Despite Agilent 
Technologies “generate(s) patent and other intellectual property rights covering significant 
inventions and other innovations in order to create a competitive advantage” (Annual report, 
FY 2008: page 16), nevertheless, his notes to consolidated financial statements do not reveal 
qualitative useful information about patents capitalized.  
 
 Other Intangible Assets  
 Gross 
Carrying 
Amount 
 Accumulated 
Amortization 
 Net Book 
Value 
 
 (in millions)  
As of October 31, 2007:          
Purchased technology $ 197  $ 90  $ 107  
Trademark/Tradename  31   1   30  
Customer relationships  67   26   41  
Total $ 295  $ 117  $ 178  
As of October 31, 2008:          
Purchased technology $ 281  $ 124  $ 157  
Trademark/Tradename  32   3   29  
Customer relationships  85   43   42  
Total $ 398  $ 170  $ 228  
 
We purchased $103 million of other intangibles and recorded $67 million of goodwill during 2008 relating to seven 
acquisitions and a purchase of the remaining unowned portion of a joint venture. Pro forma disclosures were not 
required for these acquisitions, as they were not material. Amortization of intangible assets was $53 million in 2008, 
$40 million in 2007, and $24 million in 2006. Future amortization expense related to existing purchased intangible 
assets is estimated to be $47 million in 2009, $43 million for 2010, $39 million for 2011, $31 million for 2012, $21 
million for 2013, and $47 million thereafter. On December 18, 2007, we completed the acquisition of Velocity11, a 
designer, manufacturer and marketer of robotic solutions. The aggregate purchase price was approximately $111 
million in cash used to purchase 100 percent of Velocity11's outstanding common shares and vested common stock 
options that Velocity11 employees held on the closing date of the acquisition.” 
 
Although “purchased technology” represents more than 50% of total other intangible assets, the 
company does not disclose detailed information regarding its composition or how this asset 
could contribute to firm’s competitive advantage. For those patents to be expensed in the 
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income statement, Agilent Technologies describes the different research projects carried on and 
states “Due to the breadth of research and development projects across all of our businesses, 
there are a number of drivers of this expense” (Annual report, FY 2008: page 43). Nevertheless, 
the notes to consolidated financial statements instead of providing useful indication on what is 
financial magnitude of each research projects, describe only the overall amount of total 
expenditures.  
 
Source: Agilent Technologies Inc., Annual report for the fiscal year ended October 31, 2008: page 89. 
 
 
The three-abovementioned problems mostly stem from a mismatch between the 
economic attributes of patents and the accounting criteria set for their recognition in the 
balance sheet (Lev, 2001). Above all, the inherently high risk of patents negatively 
affects the firm’s ability to estimate in a reliable way their future benefits. This in turns, 
often results into a full expensing of patents in the income statement.  
 
3. Recognition of patents 
The accounting valuation of patents is set by accounting standards related to intangible 
assets that are the International Accounting Standard No. 38 “Intangible Assets” 
(hereby IAS 38) for IFRS, and the FASB Concepts Statement No. 142 “Goodwill and 
Other Intangible Assets” (hereby FASB 142) for U.S. GAAP.  
The initial recognition is the process of incorporating in the balance sheet a patent that 
satisfies certain criteria. As regards IFRS, in order to recognize patents as balance sheet 
assets, IAS 38 requires a company to demonstrate that:  
1. the patent meets the definition of an intangible asset (existence of future economic 
benefits, control and identifiability); 
2. it is probable that the expected future economic benefits that are attributable to the 
patent will flow to the entity;  
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3. the cost of the patent can be measured reliably. 
As regards the definition of intangible asset, IAS 38 prescribes that an intangible asset 
shall be recognized only when the three conditions are satisfied:  
a) existence of future economic benefits,  
b) control, and  
c) identifiability. 
The existence of future economic benefits is regarded as precondition to define an 
intangible assets. In particular the future economic benefits flowing from an intangible 
asset may include not only revenues from the sale of products or services, but also cost 
savings and other benefits resulting from the use of the asset (IAS 38, par. 17). For 
example, the use of a patent in a production process reduces future production costs 
rather than increase future revenues.  
The control criterion refers to the company’s ability to obtain future economic benefits 
and to restrict the access of others to those benefits (IAS 38, par. 13). The capacity of 
control the future economic benefits from an intangible asset generally arises from legal 
rights that are enforceable in a court of law. Therefore control criterion is always 
satisfied in case of patents. 
The identifiability criterion requires that an intangible asset should be distinguished 
from goodwill. In particular, an asset meets the identifiability when:  
- it is separable, that is capable of being separated or divided from the entity and sold, 
transferred, licensed, rented or exchanged, either individually or together with a 
related contract, asset or liability; or  
- when it arises from contractual or other legal rights, regardless of whether those 
rights are transferable or separable from the entity or from other rights and 
obligations (IAS 38, par. 12). 
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Besides the three-abovementioned conditions to define an intangible asset, IFRS 
specifies two criteria that qualify for recognition in the balance sheet. IAS 38 (par.21) 
clarifies that an intangible asset shall be recognised if, and only if, it is probable that the 
expected future economic benefits that are attributable to the asset will flow to the 
entity; and the cost of the asset can be measured reliably. As regards the concept of 
probability, it refers to the degree of uncertainty that the future economic benefits 
associated with the patent will flow to the company. The uncertainty that characterises 
the environment in which a company operates mostly affects the concept of probability. 
Consequently, the assessment of the degree of uncertainty of future economic benefits is 
made using reasonable and supportable assumptions that represent management’s best 
estimate of the set of economic conditions that will exist over the useful life of the 
patent (IAS 38, par. 22).  
The second criterion of reliable measurement requires that a patent possesses a cost or 
value that can be measured reliably. According to IASB Framework, information is 
reliable “when it is free from material errors and bias and can be depended upon by 
users to represent faithfully that which it either purports to represent or could reasonably 
be expected to represent” (IASB Framework, par. 31). When a patent meets the 
definition of intangible asset and the criteria of expected future economic benefits and 
reliable measurement are satisfied, the patent should be recognised in the balance sheet, 
otherwise it has to be expensed in the income statement.  
As regards the U.S GAAP, accounting for patents is substantially similar to IFRS since, 
following the Norwalk agreementii, the U.S and European standard setters (respectively, 
FASB and IASB) pledged to make their financial reporting standards fully compatible. 
Consequently, differences between IFRS and U.S GAAP have been progressively 
reduced.iii 
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U.S GAAP definition of intangible assets and the related attributes that qualify an asset 
as intangible reflect the IASB definition. FASB Concepts Statement No. 6 “Elements of 
Financial Statements” and FASB Concepts Statement No. 142 “Goodwill and Other 
Intangible Assets” state that assets are probable future economic benefits obtained or 
controlled by a particular entity as a result of past transactions or events (FASB 6, par. 
25) and intangible assets are assets that lack of physical substance (FASB No. 142, 
appendix F).  
U.S GAAP definition includes the essential characteristics of an asset described by 
IFRS: it represents future economic benefits, it is a consequence of a past transaction or 
event and it is controlled by the company. FASB Concepts Statement No. 5 
“Recognition and Measurement in Financial Statements of Business Enterprises” sets 
four criteria for recognition in the balance sheet. Consequently, in order to recognize a 
patent as an asset :iv 
- it should meet the asset definition,  
- it should have an attribute that is measurable with sufficient reliability,  
- the information about it is capable of making a difference in users’ decisions,  
- the information is representationally faithful, verifiable, and neutral.  
 
Recognition criteria are satisfied in the case of external acquisition of patent and of 
R&D, whereas research and development costs and related internally generated patents 
do not meet the abovementioned criteria and are charged to expense as incurred.  
In the case of business combination, patents always satisfy the condition for 
capitalization in the balance sheet. Actually, FASB Concepts Statement Business 
Combination” No. 141 (par. 3k) claims that an intangible assets could be capitalized 
apart from goodwill if:  
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• it arises from contractual/legal rights or  
• if it is separable, that is, it is capable of being separated or divided from the 
acquired entity and sold, transferred, licensed, rented, or exchanged.  
In particular, Statement 141 specifies that intangible assets acquired in a business 
combination that do not meet certain criteria have to be included in the amount initially 
recognized as goodwill. 
 
IFRS U.S. GAAP 
• Patent meets the definition of an intangible 
asset: 
- existence of future economic benefits, 
- control  
- identifiability 
• Patent meets the definition of asset: 
- existence of future economic benefits, 
- consequence of a past transaction or event 
- control by the company 
• It is probable that the expected future 
economic benefits that are attributable to 
the patent will flow to the entity;  
• It has an attribute that is measurable with 
sufficient reliability,  
• The cost of the patent can be measured 
reliably. 
• The information about it is capable of making 
a difference in user decisions, and  
 • The information is representationally faithful, 
verifiable, and neutral 
 
Table. 1 Recognition criteria for patents 
 
4. Initial measurement of patents 
Once recognition criteria are satisfied, accounting standards require determining the 
monetary amount at which the patent is to be recognised in the balance sheet. The initial 
measurement involves the selection of the basis of measurement, that differs between 
IFRS and U.S. GAAP and varies according to the different ways in which the asset 
arises. 
As regards IFRS, IAS 38 distinguishes whether a patent: 
- arises from an external acquisition or  
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- it is internally developed.   
 
In particular, in the case of external acquisition recognition criteria are always satisfied. 
Actually, the price paid to acquire the patent reflects both a signal about the probability 
that future economic benefits will flow to the company and, a reliable measure of the 
cost of the patent (IAS 38, par. 25-26). Conversely, in the case of internally generated 
patents, a company is less able to prove the existence of future economic benefits. 
Indeed, IAS 38 claims that it is particularly difficult to provide a reliable evaluation of 
the cost of an internally generated intangible because, in some cases, the cost cannot be 
distinguished from the cost of maintaining or enhancing the entity’s internally 
generated goodwill or of running day-to-day operations  (IAS 38, par. 51). Here we 
discuss how the initial measurement of patents changes between externally acquired 
and internally developed. 
The external acquisition of patents involves either a separate acquisition or an 
acquisition in a business combination. In particular, the IFRS “Business Combination” 
No. 3 defines a business combination as a transaction or event in which an acquirer 
obtains control of one or more businesses. A business is defined as an integrated set of 
activities and assets that is capable of being conducted and managed for the purpose of 
providing a return directly to investors or other owners, members or participants. 
In case of separate acquisition of the patent, the initial measurement is based on the 
purchase price, which could include import duties, non-refundable purchase taxes and 
any directly attributable cost (See Table 4).  
When a patent is acquired in a business combination, the initial measurement is based 
on fair value, that is the amount for which a patent could be exchanged between 
knowledgeable, willing parties in an arm’s length transaction (IAS 38, par.8). 
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According to IAS 38, the acquiring company recognises separately from goodwill a 
patent of the acquiree if the asset’s fair value can be measured reliably, irrespective of 
whether the patent had been recognised by the acquiree before the business combination 
(IAS 38, par. 34). Besides, if the patent of the acquiree is still under development, the 
acquiring company might recognize as an asset the in-process research and development 
project (IPR&D) of the acquiree if the project meets the definition of an intangible asset 
(existence of future economic benefits, control and identifiability) and its fair value can 
be measured reliably. Although for tangible and financial assets the measurement of fair 
value could be normally obtained, the economic characteristics of intangible assets 
make particularly challenging the assessment of fair value with sufficient reliability. 
This measurement requires the availability of market prices in an active market or 
purchase prices of the most recent similar transactions.v Nevertheless, as IAS 38 
specifies, it is uncommon that for patents an active market with public prices exists.vi 
Moreover, as already discussed in Chapter 6, given the uniqueness of most patents and 
the scarce frequency of transactions, purchasing prices of similar patents may not 
provide sufficient evidence of the fair value. Consequently, in the absence of an active 
market and of exchange transactions for the same or similar patents, companies may use 
two main techniques for estimating fair values indirectly (IAS 38, par. 41). These 
valuation methods have been discussed in Chapter 6 and include the discounted cash 
flows method and the adoption of multiples reflecting current market transactions to 
indicators that drive the profitability of the patent (such as revenue, market shares and 
operating profit) or to the royalty stream that could be obtained from licensing the 
patent (as in the ‘relief from royalty’ approach). In particular, IAS 38 states that these 
valuation methods may be used for initial measurement in a business combination if 
their objective is to estimate fair value and if they reflect current transactions and 
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practices in the industry (See Box 2 for an example).  
 
Box 2 – Estimation of fair value 
 
The 2008 annual report of Bayer (page 157) states that: 
“the estimation of discounted cash flows from intangible assets is based on assumptions 
concerning: 
- the outcomes of research and development activities regarding compound efficacy, results of 
clinical trials, 
- the probability of obtaining regulatory approval in individual countries,  
- long-term sales trends, 
- possible selling price erosion due to generic competition in the market following patent 
expirations, 
- the behavior of competitors (launch of competing products, marketing initiatives etc.).” 
Source: Bayer 2008 Annual report: page 157. 
 
As regards internally generated patents, IFRS admit their capitalization among 
development costs. Specifically, given the general difficulties in establishing whether an 
internally generated intangible asset meets the criteria for recognition, IFRS divides the 
generation process into a research phase and a development phase (See Table 2 for 
examples of research and development activities).vii IAS 38 does not allow the 
capitalization of expenditures incurred during the research phase because a company 
cannot demonstrate that research activities will generate probable future economic 
benefits. Therefore, expenditures on research phase have to be reported in the income 
statement. The development phase is characterized by less uncertainty on future 
economic benefits and then the related expenditures could be capitalized in the balance 
sheet. However, if it is not possible to identify clearly when the development phase 
begins, the company has to treat the expenditure on the project as if it were incurred in 
the research phase only. 
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IFRS 
Research activities: 
Activities aimed at obtaining new knowledge; 
The search for, evaluation and final selection of, applications of research findings or other knowledge; 
The search for alternatives for materials, devices, products, processes, systems or services; 
The formulation, design, evaluation and final selection of possible alternatives for new or improved 
materials, devices, products, processes, systems or services; 
Development activities: 
Design, construction and testing of pre-production or pre-use prototypes and models; the design of tools, 
jigs, moulds and dies involving new technology; 
Design, construction and operation of a pilot plant that is not of a scale economically feasible for 
commercial production;  
Design, construction and testing of a chosen alternative for new or improved materials, devices, products, 
processes, systems or services. 
U.S. GAAP 
Activities included in R&D: 
Laboratory research aimed at discovery of new knowledge. 
Searching for applications of new research findings or other knowledge. 
Conceptual formulation and design of possible product or process alternatives. 
Testing in search for or evaluation of product or process alternatives. 
Modification of the formulation or design of a product or process. 
Design, construction, and testing of preproduction prototypes and models. 
Design of tools, jigs, molds, and dies involving new technology. 
Design, construction, and operation of a pilot plant that is not of a scale economically feasible to the 
enterprise for commercial production. 
Engineering activity required to advance the design of a product to the point that it meets specific 
functional and economic requirements and is ready for manufacture. 
Activities excluded in R&D: 
Engineering follow-through in an early phase of commercial production. 
Quality control during commercial production including routine testing of products. 
Trouble-shooting in connection with breakdowns during commercial production. 
Routine, on-going efforts to refine, enrich, or otherwise improve upon the qualities of an existing product. 
Adaptation of an existing capability to a particular requirement or customer’s need as part of a continuing 
commercial activity. 
Seasonal or other periodic design changes to existing products. 
Routine design of tools, jigs, molds, and dies. 
Activity, including design and construction engineering, related to the construction, relocation, 
rearrangement, or start-up of facilities or equipment other than (1) pilot plants and (2) facilities or 
equipment whose sole use is for a particular research and development project. 
Legal work in connection with patent applications or litigation, and the sale or licensing of patents. 
 
Source: FASB Statement No. 2, Accounting for Research and Development Costs, paragraphs 9-10; 
International Accounting Standards Board (IASB), IAS 38 Intangible assets, paragraphs 56,59. 
 
Table. 2 Examples of research and development activities under IFRS 
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In particular, an intangible asset arising from development phase shall be recognised if, 
and only if, a company can demonstrate all the following conditions (IAS 38, par. 57): 
- the technical feasibility of completing the patent so that it will be available for use or 
sale. 
- its intention to complete the patent and use or sell it. 
- its ability to use or sell the patent. 
- how the patent will generate probable future economic benefits. Among other things, 
the entity can demonstrate the existence of a market for the output of the patent or 
the patent itself or, if it is to be used internally, the usefulness of the patent. 
- the availability of adequate technical, financial and other resources to complete the 
development and to use or sell the patent. 
- its ability to measure reliably the expenditure attributable to the patent during its 
development. 
Although IFRS allow capitalizing development costs, companies are seldom able to 
demonstrate that all the abovementioned conditions are satisfied. Actually, the 
management must use its judgment to evaluate whether technical and economic 
characteristics of each development project satisfy the accounting requirements. For 
example, the technical feasibility of completing a patent could be demonstrated in 
pharmaceutical and biotech industries by the regulatory approval of products. In 
particular, some companies consider as a strong indication that the above criteria are 
met and hence as starting point for the capitalisation of internal development costs when 
a filing for approval had been made in a major market and approval was considered 
highly probable (see Box 3 for an example).  
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Box  3- Capitalization of development costs 
 
In the 2008 annual report GlaxoSmithKline (page 108) states:  
“Research and development expenditure is charged to the income statement in the period in 
which it is incurred. Development expenditure is capitalised when the criteria for recognising 
an asset are met, usually when a regulatory filing has been made in a major market and 
approval is considered highly probable.”   
 
In other cases, the regulatory approval might not provide a sufficient basis for capitalising the 
development costs as Merck KGaA 2008 annual report testifies (page 85):  
“The costs of research and development are expensed in full in the period in which they are 
incurred. Development expenses in the Pharmaceuticals business sector cannot be capitalized 
since the high level of risk up to the time that pharmaceutical products are marketed means that 
the requirements of IAS 38 are not satisfied in full. Costs incurred after regulatory approval are 
insignificant. In the same way, the risks involved until products are marketed means that 
development expenses in the Chemicals business sector cannot be capitalized.” 
 
Source: GlaxoSmithKline 2008 Annual report: page 108; Merck KGaA 2008 Annual report: page 85. 
 
In order to demonstrate the technical and commercial feasibility a company should 
constantly assess the potential market during the various stages of development and 
evaluate whether its competitors might have marketed similar products or technologies 
that consequently undermine the probability of economic benefits. Moreover, IAS 38 
indicates that a business plan showing the technical, financial and other resources 
needed in the development project could provide evidence of the availability of 
resources to complete and use an intangible asset. As well, a lender’s indication of its 
willingness to fund the plan could demonstrate the availability of external finance. 
Once the criteria for capitalisation have been met, the cost of an internally generated 
patent comprises all directly attributable costs necessary to create, produce, and prepare 
the patent to be capable of operating in the manner intended by management. 
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Internally generated patents 
Initial measurement → Production cost  
Attributable costs: Not attributable costs: 
• Costs of materials and services used or 
consumed in generating the patent; 
• Selling, administrative and other general 
overhead expenditure unless this expenditure 
can be directly attributed to preparing the patent 
for use; 
• Employee benefits for the personnel involved in 
the generation of the patent; 
• Expenditure on training staff;  
• Directly attributable costs of patent application: 
fees to register or transfer a legal right; 
• Patent defence costs. 
• Design, construction and testing of pre-
production prototypes and models. 
 
Externally acquired patents 
Initial measurement → Separate Acquisition: Purchase price  
  → Business Combination: Fair value 
Attributable costs: Not attributable costs: 
• Purchase price, including import duties and non-
refundable purchase taxes, after deducting trade 
discounts and rebates; 
• Costs incurred in using or redeploying a patent; 
• Costs of employee benefits and professional fees. • Initial operating losses, such as those incurred 
while demand for the patent’s output builds up; 
 • Costs of introducing a new product or service 
(including costs of advertising and promotional 
activities); 
 • Administration and other general overhead 
costs. 
Source: IAS 38 Intangible assets, paragraphs 27-29, 66-67.  
 
Table. 3 Initial measurements according to IFRS 
 
As regards the U.S GAAP, the initial measurement of patents is substantially similar to 
IFRS for what concerns external acquisitions of patents and R&D acquired in a business 
combination. As discussed in the previous section, U.S GAAP exclude from recognition 
in the balance sheet expenditures in the development stage and related internally 
generated patents. 
The initial measurement of patents and R&D acquired in a business combination is 
based on fair value, which is defined in paragraph 5 of FASB Statement “Fair Value 
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Measurements” No. 157 as the price that would be received to sell an asset or paid to 
transfer a liability in an orderly transaction between market participants at the 
measurement date. FASB Concepts Statement No. 142 “Goodwill and Other Intangible 
Assets” specifies that the fair value of an intangible asset shall be determined based on 
the assumptions that market participants would use in pricing the asset. Besides, the 
cost of a group of assets acquired in a transaction other than a business combination is 
allocated to the individual assets acquired on the basis of the relative fair values and 
shall not give rise to goodwill.  
The initial measurement at fair value under U.S. GAAP substantially reflects the 
indications of IFRS previously discussed. In particular, companies generally apply the 
discounted cash flows method in the measurement of fair value. Examples of initial 
measurement at fair value can be found in Box 4.  
 
Box 4 - Initial measurement at fair value 
 
In the 2007 annual report of Merck Sharpe and Dhome, we find the following (page 10): 
“The fair value of intangible assets, including acquired research, is based on significant 
judgments made by management, and accordingly, for significant items, the Company typically 
obtains assistance from third party valuation specialists. […] For intangible assets, including 
acquired research, the Company typically uses the income approach, which estimates fair value 
based on each project’s projected cash flows. Future cash flows are predominately based on a 
net income forecast of each project, consistent with historical pricing, margins and expense 
levels of similar products. Revenues are estimated based on relevant market size and growth 
factors, expected industry trends, individual project life cycles, and the life of each research 
project’s underlying patent, if any. Expected revenues are then adjusted for the probability of 
technical and marketing success and the resulting cash flows are discounted at a risk-adjusted 
discount rate.”  
 
Similarly, Motorola states in 2007 annual report (page 126): 
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“The value to in-process research and development was determined using expected future cash 
flows discounted at average risk adjusted rates reflecting both technological and market risk as 
well as the time value of money. Historical pricing, margins and expense levels, where 
applicable, were used in the valuation of the in-process products. The in-process research and 
development acquired will have no alternative future uses if the products are not feasible.”  
Source: Merck Sharpe and Dhome 2007 Annual report: page 10; Motorola 2007 Annual report: page 126. 
 
 
4. Measurement of patents after initial recognition: amortization and impairment 
test 
 
The measurement of patents after the initial recognition require firstly the definition of 
useful life of the patents. In particular, according to IAS 38 the useful life is: 
a) the period over which an asset is expected to be available for use by an entity; or 
b) the number of production or similar units expected to be obtained from the asset by 
an entity. 
FASB Concepts Statement No. 142 “Goodwill and Other Intangible Assets” provides a 
similar definition claiming that useful life is the period over which the asset is expected 
to contribute directly or indirectly to the future cash flows of that entity. 
In particular, both IFRS and U.S GAAP require defining whether the useful life of an 
intangible asset is finite or indefinite and, consequently, assessing the period over which 
the asset is expected to generate net cash inflows for the company. In the estimation of 
useful life, companies should consider several factors that entail economic, 
technological and legal characteristics of intangible assets (see Table 5). Based on an 
analysis of these relevant factors, an intangible asset is regarded as having an indefinite 
useful life when there is no foreseeable limit to the period over which the asset is 
expected to generate future economic benefits. However, in the case of patents, the 
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future profitability is limited by legal terms that restrict the period over which the 
company controls the economic benefits. In particular, IAS 38 states the useful life shall 
not exceed the period of the contractual or other legal rights and may be shorter 
depending on the period over which the entity expects to use the asset.viii Similarly, 
FASB Concepts Statement No. 142 claims that the useful life of the asset is considered 
to be indefinite if no legal, regulatory, contractual, competitive, economic, or other 
factors limit the useful life of an intangible asset to the reporting entity. Thus, patents 
are generally considered as having a finite useful life. 
 
Factors determining the useful life: 
IFRS: 
• The expected usage of the asset by the entity and whether the asset could be managed efficiently by 
another management team; 
• Typical product life cycles for the asset and public information on estimates of useful lives of similar 
assets that are used in a similar way; 
• Technical, technological, commercial or other types of obsolescence; 
• The stability of the industry in which the asset operates and changes in the market demand for the 
products or services output from the asset; 
• Expected actions by competitors or potential competitors; 
• The level of maintenance expenditure required to obtain the expected future economic benefits from the 
asset and the entity’s ability and intention to reach such a level; 
• The period of control over the asset and legal or similar limits on the use of the asset, such as the expiry 
dates of related leases; and 
• Whether the useful life of the asset is dependent on the useful life of other assets of the entity. 
U.S. GAAP: 
• The expected use of the asset by the entity; 
• The expected useful life of another asset or a group of assets to which the useful life of the intangible 
asset may relate; 
• Any legal, regulatory, or contractual provisions that may limit the useful life; 
• The entity’s own historical experience in renewing or extending similar arrangements regardless of 
whether those arrangements have explicit renewal or extension provisions. In the absence of that 
experience, the entity shall consider the assumptions that market participants would use about renewal 
or extension (consistent with the highest and best use of the asset by market participants), adjusted for 
entity-specific factors. 
• The effects of obsolescence, demand, competition, and other economic factors (such as the stability of 
the industry, known technological advances, legislative action that results in an uncertain or changing 
regulatory environment, and expected changes in distribution channels). 
• The level of maintenance expenditures required to obtain the expected future cash flows from the asset 
(for example, a material level of required maintenance in relation to the carrying amount of the asset 
may suggest a very limited useful life) 
Source: FASB Statement No. 142 (par. 11) and IAS 38 (par. 90). 
 20 
Table. 5 Factors determining the useful life of intangible assets 
 
Other than goodwill whose useful life is always indefinite, the identification of 
intangible asset other than patents with an indefinite useful life strictly depends upon 
company’s judgment of asset profitability.  
 
Box 5 – Example of assets with indefinite useful life 
 
For example, in the pharmaceutical industry, most of companies evaluate trademarks as assets 
having indefinite useful life regardless of their legal lives. For instance, GlaxoSmithKline states 
in the (2008 financial report page 130): 
“Indefinite life brands comprise a portfolio of Consumer Healthcare products acquired with the 
acquisitions of Sterling Winthrop, Inc. in 1994, Block Drug Company, Inc. in 2001 and CNS, 
Inc. in 2006. […] Each of these brands is considered to have an indefinite life, given the 
strength and durability of the brand and the level of marketing support. The brands are in 
relatively similar stable and profitable market sectors, with similar risk profiles, and their size, 
diversification and market shares mean that the risk of market-related factors causing a 
reduction in the lives of the brands is considered to be relatively low. The Group is not aware of 
any material legal, regulatory, contractual, competitive, economic or other factor which could 
limit their useful lives. Accordingly, they are not amortised.” 
 
In contrast, Novartis operates in the same industry of GlaxoSmithKline and evaluates acquired 
in-process research and development project as having indefinite useful life (2008 financial 
report page 183): 
“The useful lives assigned to acquired intangible assets are based on the period over which 
they are expected to generate economic benefits, commencing in the year in which they first 
generate sales or are used in development. Acquired intangible assets are amortized on a 
straight-line basis over the following periods: 
- Trademarks: over their estimated economic or legal life with a maximum of 20 years; 
- Product and marketing rights: 5 to 20 years; 
- Core development technologies: over their estimated useful life, typically 15 to 30 years; 
- Software: 3 years; 
- Others: 3 to 5 years. 
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In-Process Research & Development (IPR&D) is the only class of separately identified 
intangible assets that is not amortized, but IPR&D is tested for impairment on an annual basis 
or when facts and circumstances warrant an impairment test.” 
 
Source: GlaxoSmithKlin 2008 Annual report: page 130; Novartis 2008 Annual report: page 183. 
 
Following the definition of a finite or indefinite useful life, IFRS and U.S GAAP 
require that an intangible asset with a finite useful life be amortized, whereas an 
intangible asset with an indefinite useful life is not amortized but tested for impairment 
loss. Given that patents are generally considered as having a finite useful life, they will 
be systematically amortized over their useful lives.  
The amortisation process requires the systematic allocation of the depreciable amount 
of a patent over its useful life. Thus, amortisation requires the definition of: 
- the depreciable amount of the patent, and 
- the residual value. 
In particular, the depreciable amount represents the initial cost of patent less its residual 
value that is the estimated amount that an entity would currently obtain from disposal of 
the asset. However, both IFRS and US GAAP suggest to set the residual value to zero 
unless there is a commitment by a third party to purchase the patent at the end of its 
useful life; or residual value can be determined by reference to an active market for the 
asset and it is probable that such a market will exist at the end of the asset’s useful life 
(FASB 142, par. 13: IAS 38 par. 100). An example of patent amortization is presented 
in Box 5. 
 
BOX 6 - Example of patent amortization 
 
A patented technology is expected to be a source of net cash inflows for at most 20 years. The 
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carrying amount of the patent, that is the amount at which the patent is recognised in the 
balance sheet, is $100.000.  
The company has a commitment from a third party to purchase that patent in five years for 60 
per cent of the value of the patent at the date it was acquired, and the entity intends to sell the 
patent in five years. 
 
Depreciable amount = carrying amount - residual value = 100.000 – 60.000 = 40.000  
Patent useful life = 5 years 
Yearly amortization rate = 40.000/5= 8.000 
 
 
 
Amortisation begins when the patent is available for use and the amortisation method 
used should reflect the pattern in which the patent’s future economic benefits are 
expected to be consumed by the company. If that pattern cannot be determined reliably, 
the straight-line method (constant depreciation) shall be used.   
IFRS and U.S GAAP require that a company review at least at each financial year-end 
the amortisation period and the amortisation method in order to estimate whether the 
expected useful life of the patent is different from previous estimates or there has been a 
change in the expected pattern of consumption of the patent’s future economic benefits.  
Moreover, IFRS and U.S GAAP also recommend testing patents for impairment 
whenever there is an indication that the asset may be impaired. 
As regards intangible asset with an indefinite useful life, IFRS and U.S GAAP require 
that they will not be amortised but only tested for impairment loss. It should be noted 
that rarely a patent is judged to have an indefinite useful life, therefore the adoption of 
the impairment test to measure patent value after initial recognition is quite rare.  
While the accounting requirements for amortization are consistent between IFRS and 
U.S GAAP, slight differences exist in definition of impairment test between the two 
accounting standards. 
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Under U.S. GAAP the impairment test consists of a comparison of the carrying amount 
of an intangible asset with its fair value measured as undiscounted cash flows. Thus, the 
impairment test consists of a comparison of the fair value of an intangible asset with its 
carrying amount that is the amount at which an asset is recognised in the balance sheet. 
If the carrying amount of an intangible asset exceeds its fair value, an impairment loss 
shall be recognized in an amount equal to that excess. Subsequent reversal of a 
previously recognized impairment loss is prohibited. 
According to IFRS, impairment test is performed comparing the carrying amount of an 
asset with the recoverable amount, which is the is the higher between the asset’s fair 
value less costs to sell and the asset’s value in use. In particular, value in use represents 
the future cash flows discounted to present value by using a pretax, market-determined 
rate that reflects the current assessment of the time value of money and the risks specific 
to the asset for which the cash flow estimates have not been adjusted. Thus, only if the 
carrying amount of the asset exceeds the recoverable amount, an impairment loss for the 
difference is recognized. 
 
 
6. Conclusions 
This chapter has examined the issue of accounting valuation of patents highlighting the 
main similarities and differences between IFRS and U.S. GAAP.  
Whereas previous chapters have focused on the economic valuation of patents, this 
chapter has firstly identified the general problems of evaluating patents for accounting 
purposes. In particular, it has discussed the shortcomings stemming from the 
measurement of patents both at historical cost and at fair value. The measurement of 
capitalized patents at historical cost provides backward-looking information. Thus, 
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financial reports supply no indication of efficiency of use and future exploitation 
potential of patents. The measurement at fair value could provide forward-looking 
information on patents since fair value is the amount for which a patent could be 
exchanged between knowledgeable, willing parties in an arm’s length transaction. 
However, the absence of public market prices of patents and the scarcity of comparable 
transaction make difficult the evaluation of patents at fair value. 
Moreover, the chapter has discussed how a company should recognize and measure 
patents highlighting the main differences between IFRS and U.S. GAAP. Although 
IFRS, differently from U.S. GAAP, could permit the capitalization among development 
costs of patents internally generated, however companies are seldom able to 
demonstrate that conditions for capitalization are satisfied.  
 
 
                                               
i In order to achieve a higher comparability of financial statements and consequently a 
broader integration of capital markets across countries, the international harmonization 
of accounting standards has been undertaken since 2002. In particular, accounting 
harmonization aims at making financial reporting consistent around the world through 
two-pronged approaches: the adoption of one single set of accounting standards and, at 
the same time, the progressive convergence between accounting standards. Regarding 
the adoption, at the present time, more than one hundred countries permit or require 
some or all firms to replacing national GAAPs with International Financial Reporting 
Standards (IFRS). Regarding convergence between accounting standards, some 
countries such as U.S., Japan, and China prefer to converge their standards with IFRS, 
so that eventually the two sets of standards will be the same. 
ii The Norwalk agreement is a memorandum of understanding issued in 2002 in which 
the FASB and the IASB formalised their commitment to the convergence of US GAAP 
and IFRS.  
iii  For example, the SEC removed the reconciliation requirement for non-U.S. 
companies that are registered in the United States and use IFRS. Recently, SEC issued a 
preliminary plan that could allow some of the largest public companies in the United 
States to use IFRSs for fiscal years ending on or after 15 December 2009 and could lead 
to mandatory transition to IFRSs for domestic issuers starting for fiscal years ending on 
or after 15 December 2014. 
iv FASB Concepts Statement No. 5 specifies also that recognition criteria are subject to 
a pervasive cost-benefit constraint: the expected benefits from recognizing a particular 
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item should justify perceived costs of providing and using the information. Recognition 
is also subject to a materiality threshold: an item and information about it need not be 
recognized in a set of financial statements if the item is not large enough to be material 
and the aggregate of individually immaterial items is not large enough to be material to 
those financial statements. 
v IAS 38 defines active market as a market in which all the following conditions exist: 
(a) the items traded in the market are homogeneous; 
(b) willing buyers and sellers can normally be found at any time; and 
(c) prices are available to the public. 
vi For example, in some jurisdictions, an active market may exist for freely transferable 
taxi licences, fishing licences or production quotas. However, an active market cannot 
exist for brands, newspaper mastheads, music and film publishing rights, patents or 
trademarks, because each such asset is unique. (IAS 38 Intangible assets, paragraph 78). 
vii Specifically, research is conceived as an original and planned investigation 
undertaken with the prospect of gaining new scientific or technical knowledge and 
understanding. Conversely, the development phase is the application of research 
findings to a plan or design for the production of new or substantially improved 
materials, devices, products, processes, systems or services before the start of 
commercial production or use. 
viii Besides, IAS 38 states that If the contractual or other legal rights are conveyed for a 
limited term that can be renewed, the useful life of the intangible asset shall include the 
renewal period(s) only if there is evidence to support renewal by the entity without 
significant cost. (IAS 38 Intangible assets, paragraph 94) 
